Establishment of a three-dimensional floating cell culture system for screening drugs targeting KRAS-mediated signaling molecules

Anticancer Research

Volumn 35, Issue 8, 2015, Pages 4453-4460

  Tsunoda, Toshiyuki ^a   Ishikura, Shuhei ^a   Doi, Keiko ^a   Iwaihara, Yuri ^a   Hidesima, Hiromasa ^a   Luo, Hao ^a   Hirose, Yumiko ^a   Shirasawa, Senji ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

3 dimensional floating culture; Colorectal cancer; Drug screening; KRAS

Indexed keywords

CASPASE 3; CASPASE 7; K RAS PROTEIN; RESVERATROL; ROLIPRAM; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SCREENING; GENE EXPRESSION; GENE MUTATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS INFECTION; SIGNAL TRANSDUCTION; THREE DIMENSIONAL FLOATING CELL CULTURE; TUMOR SPHEROID; WILD TYPE; COLORECTAL NEOPLASMS; CULTURE TECHNIQUE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84939826115     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sideris M and Papagrigoriadis S: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res 34: 2061-2068, 2014.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
3. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
4. Milburn MV, Tong L, deVos AM, Brunger A, Yamaizumi Z, Nishimura S and Kim SH: Molecular switch for signal transduction: Structural differences between active and inactive forms of protooncogenic ras proteins. Science 247: 939-945, 1990.
5. Rodriguez-Viciana P, Sabatier C and McCormick F: Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 24: 4943-4954, 2004.
6. Al-Mulla F, Milner-White EJ, Going JJ and Birnie GD: Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187: 433- 438, 1999.
7. Shirasawa S, Furuse M, Yokoyama N and Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88, 1993.
8. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A, Song X, Ulrich CM, Sasazuki T, Shirasawa S and Grady WM: TGF-beta Receptor Inactivation and mutant Kras induce intestinal neoplasms in mice via a betacatenin- independent pathway. Gastroenterology, 2009.
9. Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T and Stokoe D: Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. J Biol Chem 288: 2403- 2413, 2013.
10. Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T and Shirasawa S: Oncogenic KRAS regulates miR-200c and miR- 221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res 31: 2453-2459, 2011.
11. Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S and Tsunoda T: KRAS upregulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 32: 2271-2275, 2012.
12. O'Brien LE, Zegers MM and Mostov KE: Opinion: Building epithelial architecture: Insights from three-dimensional culture models. Nat Rev Mol Cell Biol 3: 531-537, 2002.
13. Griffith LG and Swartz MA: Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7: 211-224, 2006.
14. Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T and Shirasawa S: Threedimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia 12: 397-404.
15. Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S and Shirasawa S: Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Mol Cancer 11: 46, 2012.
16. Tsunoda T, Ishikura S, Doi K, Matsuzaki H, Iwaihara Y and Shirasawa S: Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. Anticancer Res 34: 4551-4555, 2014.
17. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E and Sasazuki T: Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 60: 6886-6889, 2000.
18. Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A and Shirasawa S: KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res 31: 2535-2539, 2011.
19. Yoshida Y, Tsunoda T, Doi K, Fujimoto T, Tanaka Y, Ota T, Ogawa M, Matsuzaki H, Kuroki M, Iwasaki A and Shirasawa S: ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. Anticancer Res 32: 2301-2308, 2012.
20. Tsunoda T, Inokuchi J, Baba I, Okumura K, Naito S, Sasazuki T and Shirasawa S: A novel mechanism of nuclear factor ?B activation through the binding between inhibitor of nuclear factor-?Bα and the processed NH2-terminal region of Mig-6. Cancer Res 62: 5668-5671, 2002.
21. Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld- Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A and Eckert C: Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 124: 3420-3430, 2014.
22. Asthana A and Kisaalita WS: Microtissue size and hypoxia in HTS with 3D cultures. Drug Discov Today 17: 810-817, 2012.
23. Kunz-Schughart LA, Freyer JP, Hofstaedter F and Ebner R: The use of 3-D cultures for high-throughput screening: The multicellular spheroid model. J Biomol Screen 9: 273-285, 2004.
24. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D and Eccles SA: Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 10: 29, 2012.